NRx Pharmaceuticals Stock Rises 33% on Psychiatry Clinic Acquisition

Dow Jones

01-03

By Katherine Hamilton

NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute.

The stock rose Thursday to $2.92, reaching a six-month high. Shares are down 36% over the past 12 months.

Kadima, based in La Jolla, Calif., is expected to become the flagship clinic for Hope Therapeutics, a mental-health-services subsidiary of NRx. Hope is planning to develop an international network of psychiatry clinics designed to treat depression, anxiety and post-traumatic stress disorder.

Once the acquisition is complete, David Feifel, Kadima's founder and chief executive, will serve as chief medical innovation officer of Hope.

Kadima was among the first psychiatry clinics to use ketamine therapy to treat central-nervous-system disorders. It also has a research division and contracts with the Department of Veterans Affairs.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

January 02, 2025 12:22 ET (17:22 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2500497283"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500497283\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2500497283?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-03 01:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500497283","market":"hk","top_or_hot":-1,"title":"NRx Pharmaceuticals Stock Rises 33% on Psychiatry Clinic Acquisition","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute. \n</p>\n<p>\n  The stock rose Thursday to $2.92, reaching a six-month high. Shares are down 36% over the past 12 months. \n</p>\n<p>\n  Kadima, based in La Jolla, Calif., is expected to become the flagship clinic for Hope <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a mental-health-services subsidiary of NRx. Hope is planning to develop an international network of psychiatry clinics designed to treat depression, anxiety and post-traumatic stress disorder. \n</p>\n<p>\n  Once the acquisition is complete, David Feifel, Kadima's founder and chief executive, will serve as chief medical innovation officer of Hope. \n</p>\n<p>\n  Kadima was among the first psychiatry clinics to use ketamine therapy to treat central-nervous-system disorders. It also has a research division and contracts with the Department of Veterans Affairs. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 02, 2025 12:22 ET (17:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NRx Pharmaceuticals Stock Rises 33% on Psychiatry Clinic Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNRx Pharmaceuticals Stock Rises 33% on Psychiatry Clinic Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-03 01:22</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute. \n</p>\n<p>\n  The stock rose Thursday to $2.92, reaching a six-month high. Shares are down 36% over the past 12 months. \n</p>\n<p>\n  Kadima, based in La Jolla, Calif., is expected to become the flagship clinic for Hope <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, a mental-health-services subsidiary of NRx. Hope is planning to develop an international network of psychiatry clinics designed to treat depression, anxiety and post-traumatic stress disorder. \n</p>\n<p>\n  Once the acquisition is complete, David Feifel, Kadima's founder and chief executive, will serve as chief medical innovation officer of Hope. \n</p>\n<p>\n  Kadima was among the first psychiatry clinics to use ketamine therapy to treat central-nervous-system disorders. It also has a research division and contracts with the Department of Veterans Affairs. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 02, 2025 12:22 ET (17:22 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRXP","symbol_name":"NRX Pharmaceuticals Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2500497283","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500497283","pubTimestamp":1735838520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute.The stock rose Thursday to $2.92, reaching a six-month high. Shares are down 36% over the past 12 months.Kadima, based in La Jolla, Calif., is expected to become the flagship clinic for Hope Therapeutics, a mental-health-services subsidiary of NRx. Hope is planning to develop an international network of psychiatry clinics designed to treat depression, anxiety and post-traumatic stress disorder.Once the acquisition is complete, David Feifel, Kadima's founder and chief executive, will serve as chief medical innovation officer of Hope.Kadima was among the first psychiatry clinics to use ketamine therapy to treat central-nervous-system disorders. It also has a research division and contracts with the Department of Veterans Affairs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"NRx Pharmaceuticals股价因收购精神病诊所而上涨33%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  NRx Pharmaceuticals shares gained after the company said it would buy California psychiatry clinic Kadima Neuropsychiatry Institute. \n\n\n  The stock rose Thursday to $2.92, reaching a six-month high. Shares are down 36% over the past 12 months. \n\n\n  Kadima, based in La Jolla, Calif., is expected to become the flagship clinic for Hope Therapeutics, a mental-health-services subsidiary of NRx. Hope is planning to develop an international network of psychiatry clinics designed to treat depression, anxiety and post-traumatic stress disorder. \n\n\n  Once the acquisition is complete, David Feifel, Kadima's founder and chief executive, will serve as chief medical innovation officer of Hope. \n\n\n  Kadima was among the first psychiatry clinics to use ketamine therapy to treat central-nervous-system disorders. It also has a research division and contracts with the Department of Veterans Affairs. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 02, 2025 12:22 ET (17:22 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1}}}